A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

William J. Gradishar; Nicholas J. Vogelzang; Lary J. Kilton; Steven J. Leibach; Alfred W. Rademaker; Suzanne French; Al B. Benson

doi:10.1007/BF00872868

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

William J. Gradishar^*, Nicholas J. Vogelzang, Lary J. Kilton, Steven J. Leibach, Alfred W. Rademaker, Suzanne French, Al B. Benson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m² administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

Original language	English (US)
Pages (from-to)	171-174
Number of pages	4
Journal	Investigational New Drugs
Volume	13
Issue number	2
DOIs	https://doi.org/10.1007/BF00872868
State	Published - Jun 1 1995

Keywords

echinomycin
metastatic
sarcoma

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00872868

Cite this

@article{eb5de591dc734c07a35dda2761efc91c,

title = "A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study",

abstract = "Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.",

keywords = "echinomycin, metastatic, sarcoma",

author = "Gradishar, {William J.} and Vogelzang, {Nicholas J.} and Kilton, {Lary J.} and Leibach, {Steven J.} and Rademaker, {Alfred W.} and Suzanne French and Benson, {Al B.}",

year = "1995",

month = jun,

day = "1",

doi = "10.1007/BF00872868",

language = "English (US)",

volume = "13",

pages = "171--174",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

AU - Gradishar, William J.

AU - Vogelzang, Nicholas J.

AU - Kilton, Lary J.

AU - Leibach, Steven J.

AU - Rademaker, Alfred W.

AU - French, Suzanne

AU - Benson, Al B.

PY - 1995/6/1

Y1 - 1995/6/1

N2 - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

AB - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

KW - echinomycin

KW - metastatic

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0028844387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028844387&partnerID=8YFLogxK

U2 - 10.1007/BF00872868

DO - 10.1007/BF00872868

M3 - Article

C2 - 8617582

AN - SCOPUS:0028844387

SN - 0167-6997

VL - 13

SP - 171

EP - 174

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this